NASDAQ
SCTX
Last Price
US $20.37
Valuation
Financial
Performance
Cash flow to debt coverage
Scribe Therapeutics Inc. balance-sheet data unavailable; cash-flow debt coverage cannot be computed.
Free cash flow growth
Scribe Therapeutics Inc. has insufficient data to evaluate this check.
Debt-to-equity ratio
Scribe Therapeutics Inc. has insufficient data to evaluate this check.
Debt-to-equity trend
Scribe Therapeutics Inc. has insufficient data to evaluate this check.
Net debt to EBITDA
Scribe Therapeutics Inc. has negative EBITDA, making leverage ratio unreliable
Interest coverage
Scribe Therapeutics Inc. interest expense data unavailable for the most recent period; interest coverage ratio cannot be reliably computed.
Profit margin growth
Scribe Therapeutics Inc. has insufficient data to evaluate this check.
Current ratio
Scribe Therapeutics Inc. has insufficient data to evaluate this check.
Return on assets
Scribe Therapeutics Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Return on equity
Scribe Therapeutics Inc.'s return on equity of 0.00%, is lower than 15.00%, indicating bad performance
Earnings quality
Scribe Therapeutics Inc. has insufficient data to evaluate this check.
Earnings stability
Scribe Therapeutics Inc. has insufficient public price history to evaluate earnings stability.
Positive free cash flow
Scribe Therapeutics Inc. has negative free cash flow, indicating the company is burning cash rather than generating it
Free cash flow yield
Scribe Therapeutics Inc. has a free cash flow yield of 0.00%, which is below the 2.00% threshold, indicating limited cash return relative to market value
Earnings growth
Scribe Therapeutics Inc. has insufficient data to evaluate this check.
Revenue growth
Scribe Therapeutics Inc. has insufficient data to evaluate this check.
Return on invested capital
ROIC is unavailable for Scribe Therapeutics Inc.; this check cannot be evaluated.
3-year revenue CAGR
Scribe Therapeutics Inc. has insufficient revenue history to calculate 3-year revenue CAGR.
Revenue consistency
Scribe Therapeutics Inc. has insufficient public price history to evaluate revenue consistency.
Return on equity consistency
Scribe Therapeutics Inc. has insufficient public price history to evaluate ROE consistency.
Cash Flow Valuation (DCF)
Scribe Therapeutics Inc. has insufficient data to evaluate this check.
Earnings yield (TTM)
Scribe Therapeutics Inc. has insufficient data to evaluate this check.
EBITDA Valuation
Scribe Therapeutics Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
EV/EBITDA (FY)
Scribe Therapeutics Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
PEG ratio (TTM/FY)
Scribe Therapeutics Inc. has insufficient data to calculate the PEG ratio.
Price-to-book ratio (FY)
Scribe Therapeutics Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails
Price-to-sales ratio (TTM)
Scribe Therapeutics Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
-
Return on equity
ROIC: -
Valuation History
-
Price to Earnings
EV/EBITDA: -
Cash flow
Profit margin
-
Fair Value
Market $20.37
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.